NASI, Theseus announce technical milestone

Article

North American Scientific and Theseus Imaging reported that clinical trials of Theseus’ Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit

North American Scientific and Theseus Imaging reported that clinical trials of Theseus’ Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit has been used in nuclear medicine procedures in more than 3500 hospitals across the U.S.

Patients who undergo heart transplants can have up to 15 catheterization procedures during the first year after the surgery to evaluate the immunosuppression medication’s effectiveness, according to the two companies. Theseus hopes Apomate will contribute equivalent information noninvasively by imaging the functional changes that occur when the body rejects an organ.

North American and Theseus signed a merger agreement in October, which is subject to final due diligence, according to Chatsworth, CA-based NASI. Theseus develops radiopharmaceutical products for in vivo medical imaging.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.